← Back to patent-cliff list
CAS 761446-44-0
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Codes: AVAPR-017, DCC-2618-005, ERDA-002, GLUME-002
Application context (from source-drug indications)
Systemic mastocytosisAvapritinibGastrointestinal stromal tumourAvapritinibMast cell leukaemiaAvapritinibGastrointestinal stromal tumourRipretinibUrothelial carcinomaErdafitinibUrinary tract neoplasmErdafitinibNon-small cell lung cancerGlumetinibSolid tumourGlumetinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Avapritinib | Tier C — Watch / trade | 2032 |
| Ripretinib | Tier C — Watch / trade | 2032 |
| Erdafitinib | Tier C — Watch / trade | 2030 |
| Glumetinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine→6-bromopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one→(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine→ethyl 2-chloropyrimidine-5-carboxylate→tert-butyl piperazine-1-carboxylate→ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate→2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid→N,O-dimethylhydroxylamine→tert-butyl 4-(5-(methoxy(methyl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate→(4-fluorophenyl)magnesium bromide→tert-butyl 4-(5-(4-fluorobenzoyl)pyrimidin-2-yl)piperazine-1-carboxylate→(4-fluorophenyl)(2-(piperazin-1-yl)pyrimidin-5-yl)methanone hydrochloride→4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine→(4-fluorophenyl)(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)methanone→(S)-2-methylpropane-2-sulfinamide→(Z)-N-((4-fluorophenyl)(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)methylene)-2-methylpropane-2-sulfinamide→N-(1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethyl)-2-methylpropane-2-sulfinamide
N-(2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide hydrochloride→2-chloropyridin-4-ol→1,2,4-trifluoro-5-nitrobenzene→2-chloro-4-(2,5-difluoro-4-nitrophenoxy)pyridine→4-((2-chloropyridin-4-yl)oxy)-2,5-difluoroaniline→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline→1-(methoxycarbonyl)cyclopropane-1-carboxylic acid→methyl 1-((2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate→lithium 1-((2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate→N-(2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide
6-bromoquinoxaline→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→2-(1-methyl-1H-pyrazol-4-yl)-7-nitroquinoxaline→7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline→3,5-dimethoxyaniline→N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine→(2-bromoethoxy)(tert-butyl)dimethylsilane→N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine→2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethanol→2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethyl methanesulfonate→Erdafitinib
6-bromo-1H-pyrazolo[4,3-b]pyridine→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridine→6-chloroimidazo[1,2-a]pyridine-3-sulfonyl chloride→1-((6-chloroimidazo[1,2-a]pyridin-3-yl)sulfonyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridine→Glumetinib
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | 1-Methyl-4-pyrazole boronic acid pinacol ester Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.